Development and validation of stability indication RP-HPLC method for estimation of satranidazole from its formulation
By: Shirode, A. R
.
Contributor(s): Dhumal, A. P | Kadam, V. J.
Publisher: Mumbai Indian Drug Manufacture's Association - IDMA 2018Edition: Vol. 55 (10).Description: 40-48.Subject(s): PHARMACEUTICS | HPLC Satranidazole Marketed dosage form Stability studies ICH Forced degradationsSummary: A sensitive stability-indicating high performance liquid chromatography (HPLC) method was developed and validated for quantitative estimation of satranidazole (SAT), a new nitroimidazole with potent antiamoebic activity and accessible in market as tablet and dry syrup either alone or in combination with ofloxacin. The present study involves the development of simple, accurate, precise, reproducible reversed phase high performance liquid chromatography (RP-HPLC) method for determination of satranidazole from its formulation. Isocratic elution at a flow rate of 1.0 mL/min was employed on Hemochrom Intsil C-18 (250 mm× 4.6 mm, 5
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2018006 |
A sensitive stability-indicating high performance liquid chromatography (HPLC) method was developed and validated for quantitative estimation of satranidazole (SAT), a new nitroimidazole with potent antiamoebic activity and accessible in market as tablet and dry syrup either alone or in combination with ofloxacin. The present study involves the development of simple, accurate, precise, reproducible reversed phase high performance liquid chromatography (RP-HPLC) method for determination of satranidazole from its formulation. Isocratic elution at a flow rate of 1.0 mL/min was employed on Hemochrom Intsil C-18 (250 mm× 4.6 mm, 5
Click on an image to view it in the image viewer
There are no comments for this item.